Drug Trial Radar · NCT07447817
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
26
Planned (sponsor's estimate)
Start
Oct 23, 2026
Primary completion
May 24, 2030
Study completion May 24, 2030
Sponsor
- Lead sponsor
- John MascarenhasAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sobi, Inc.; Karyopharm Therapeutics Inc; National Cancer Institute (NCI)
- First posted
- Mar 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.
Conditions
- Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
Interventions
PacritinibDrug
Pacritinib 200mg twice a day (BID) by mouth (PO)
SelinexorDrug
Selinexor 60mg once weekly (QW) by mouth (PO)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in spleen volumeTime frame: Baseline and 24 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
The University of Kansas Cancer Center-Westwood
Westwood, Kansas · Not yet recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Wake Forest Baptist Health Comprehensive Cancer Center
Winston-Salem, North Carolina · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.